Published in Res Commun Chem Pathol Pharmacol on November 01, 1979
The efficacy of intensive dietary therapy alone or combined with lovastatin in outpatients with hypercholesterolemia. N Engl J Med (1993) 4.61
Drug treatment of dyslipidemias: practical guidelines for the primary care physician. Heart Dis Stroke (1994) 2.68
The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day. Am J Cardiol (1997) 1.98
Sulfonamide hepatic injury. Review of the literature and report of a case due to sulfamethoxazole. N Engl J Med (1967) 1.97
Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies. Clin Ther (2001) 1.65
Efficacy and safety of simvastatin 80 mg/day in hypercholesterolemic patients. The Expanded Dose Simvastatin U.S. Study Group. Am J Cardiol (1998) 1.56
Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial. Arch Intern Med (1994) 1.46
The meetabolism of amiloride hydroloride in man. Clin Pharmacol Ther (1969) 1.33
Evaluation of the efficacy, safety, and tolerability of ezetimibe in primary hypercholesterolaemia: a pooled analysis from two controlled phase III clinical studies. Int J Clin Pract (2003) 1.19
Hypoglycemic effects of Teucrium polium. J Ethnopharmacol (1988) 1.12
Absorption and metabolism of L-dopa by the human stomach. Eur J Clin Invest (1971) 1.07
Pesticide mortality. A Jordanian experience. Am J Forensic Med Pathol (1989) 1.07
Clinical complications of corticosteroid therapy. A selected review. Med Clin North Am (1973) 1.06
L-dopa treatment failure: explanation and correction. Br Med J (1970) 0.95
Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: two-year efficacy and safety follow-up. Am J Cardiol (1994) 0.92
Long-term blood cholesterol-lowering effects of a dietary fiber supplement. Am J Prev Med (1999) 0.89
Expanded clinical evaluation of lovastatin (EXCEL) study results: III. Efficacy in modifying lipoproteins and implications for managing patients with moderate hypercholesterolemia. Am J Med (1991) 0.88
Aflaxation B1 hydroxylation by hepatic microsomal preparations from the rhesus monkey. Food Cosmet Toxicol (1975) 0.88
Effects of fenofibrate on plasma lipoproteins in hypercholesterolemia and combined hyperlipidemia. Am J Med (1987) 0.88
The instability of isoniazid and acetylisoniazid in frozen plasma. Res Commun Chem Pathol Pharmacol (1976) 0.86
Digoxin therapy during T-tube biliary drainage in man. JAMA (1978) 0.86
Toxicity of a hepatotoxic laxative preparation in tissue culture and excretion in bile in man. Clin Pharmacol Ther (1972) 0.86
Drug interactions with fibric acids. Pharmacol Ther (1994) 0.85
Plasma levels and excretion of estrogens in urine in chronic lever disease. Gastroenterology (1975) 0.85
Increased production of apolipoprotein A-I associated with elevated plasma levels of high-density lipoproteins, apolipoprotein A-I, and lipoprotein A-I in a patient with familial hyperalphalipoproteinemia. Metabolism (1993) 0.85
Dermal and inhalation exposure to dimethoate. Arch Environ Contam Toxicol (1992) 0.84
Aflatoxicol H1: a major metabolite of aflatoxin B1 produced by human and rhesus monkey livers in vitro. Res Commun Chem Pathol Pharmacol (1975) 0.83
Infant exposure to environmental tobacco smoke: Jordan University hospital-based study. East Mediterr Health J (2009) 0.83
Effects of fenofibrate on plasma lipids. Double-blind, multicenter study in patients with type IIA or IIB hyperlipidemia. Arteriosclerosis (1986) 0.83
Effects of four doses of n-3 fatty acids given to hyperlipidemic patients for six months. J Am Coll Nutr (1991) 0.83
Enterohepatic circulation of sulindac and metabolites. Clin Pharmacol Ther (1983) 0.83
L-3,4-dihydroxyphenylalanine metabolism by the gut in vitro. Biochem Pharmacol (1971) 0.83
Cholestyramine and spironolactone and their combination in digitoxin elimination. Clin Pharmacol Ther (1980) 0.82
Quantitation of biliary excretion of drugs in man. Clin Pharmacol Ther (1982) 0.82
Delay of ovulation by meloxicam in healthy cycling volunteers: A placebo-controlled, double-blind, crossover study. J Clin Pharmacol (2006) 0.82
Lipid-altering efficacy and safety of simvastatin 80 mg/day: worldwide long-term experience in patients with hypercholesterolemia. Nutr Metab Cardiovasc Dis (2000) 0.82
Drug interactions of lipid-altering drugs. Drug Saf (1998) 0.82
Methods to assess relative reliability of diet records: minimum records for monitoring lipid and caloric intake. J Am Diet Assoc (1986) 0.81
Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels. Am J Cardiol (2000) 0.81
Dual hepatic metabolism of cerivastatin--clarifications. Am J Cardiol (1999) 0.81
Effects of dietary fish oil on platelet function and plasma lipids in hyperlipoproteinemic and normal subjects. Atherosclerosis (1988) 0.80
A two-year crossover therapeutic trial with halofenate and clofibrate. Am J Med Sci (1977) 0.80
Effects of a low saturated fat, low cholesterol fish oil supplement in hypertriglyceridemic patients. A placebo-controlled trial. Ann Intern Med (1988) 0.80
The interaction between halofenate and propranolol. Clin Pharmacol Ther (1976) 0.80
Low- vs high-dose aspirin. Effects on platelet function in hyperlipoproteinemic and normal subjects. Arch Intern Med (1986) 0.80
Effects of the ACAT inhibitor CL 277,082 on cholesterol metabolism in humans. Clin Pharmacol Ther (1990) 0.80
A clinical pharmacologist's view of drug hepatotoxicity. Pharmacol Res Commun (1977) 0.79
Inhibiting cholesterol absorption with CP-88,818 (beta-tigogenin cellobioside; tiqueside): studies in normal and hyperlipidemic subjects. J Cardiovasc Pharmacol (1997) 0.79
Experimental bases for the different hepatotoxicity of erythromycin preparations in man. J Lab Clin Med (1972) 0.79
Hepatotoxicity of phenothiazines in vitro as measured by loss of aminotransferases to surrounding media. Proc Soc Exp Biol Med (1968) 0.79
Serum lipids in normo- and hyperlipidemics after methyldopa and propranolol. Clin Pharmacol Ther (1984) 0.79
Hepatotoxic and cellular uptake interactions among surface active components of erythromycin preparations. Biochem Pharmacol (1978) 0.78
Liver cell culture toxicity and surfactant potency of erythromycin derivatives. Toxicol Appl Pharmacol (1975) 0.78
The correlation of serum levels of two transaminases with tissue levels in six vertebrate species. Comp Biochem Physiol (1968) 0.78
Probucol. Curr Atheroscler Rep (2000) 0.78
Suicide by xylene ingestion. A case report and review of literature. Am J Forensic Med Pathol (1986) 0.78
Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins, in patients with combined hyperlipidemia. Atherosclerosis (2001) 0.78
Comparative clinical therapeutic trial with two hypolipidemic drugs: lofibrate and nafenopin. Clin Pharmacol Ther (1971) 0.78
The combined effects of N-3 fatty acids and aspirin on hemostatic parameters in man. Thromb Res (1990) 0.77
Chlorpromazine uptake by isolated rat hepatocytes. Proc Soc Exp Biol Med (1979) 0.77
Positional metabolism of benzo(a)pyrene in rat placenta and maternal liver. Comparison of induction effects. Drug Metab Dispos (1986) 0.77
Differential induction of ethoxyresorufin-O-deethylase in tissues of the rat placenta. J Pharmacol Exp Ther (1986) 0.77
Enhanced low-density lipoprotein cholesterol reduction and cost-effectiveness by low-dose colestipol plus lovastatin combination therapy. Am J Cardiol (1995) 0.77
Effects of Inula viscosa leaf extracts on abortion and implantation in rats. J Ethnopharmacol (2001) 0.77
Long-term efficacy and safety of cerivastatin 0.8 mg in patients with primary hypercholesterolemia. Clin Cardiol (2001) 0.76
Cytotoxicity of phenothiazines on Chang liver cells as measured by enzyme leakage. Proc Soc Exp Biol Med (1969) 0.76
Direct relaxant effects of garlic juice on smooth and cardiac muscles. J Ethnopharmacol (1991) 0.76
The effects of colestipol tablets compared with colestipol granules on plasma cholesterol and other lipids in moderately hypercholesterolemic patients. Atherosclerosis (1995) 0.76
One-year trials with halofenate, clofibrate, and placebo. Clin Pharmacol Ther (1976) 0.76
Formation of benzo[a]pyrene-DNA adducts by microsomal enzymes: comparison of maternal and fetal liver, fetal hematopoietic cells and placenta. Chem Biol Interact (1987) 0.76
Omega-3 fatty acids in hypertriglyceridemic patients: triglycerides vs methyl esters. Am J Clin Nutr (1988) 0.76
The effect of variable fat diets and cholesterol-lowering drugs on Antithrombin III levels in hyperlipoproteinemic and normal subjects. Thromb Res (1983) 0.75
A comparative trial of clofibrate and nicotinyl alcohol tartrate in hyperlipoproteinemic patients. Am J Med Sci (1979) 0.75
Drugs for treatment of patients with high cholesterol blood levels and other dyslipidemias. Prog Drug Res (1994) 0.75
Absorption and metabolism of a selective insecticide, 2,2-dimethyl-2,3-dihydrobenzofuranyl-7 N-dimethoxyphosphinothioyl-N-methylcarbamate, in bean plants. Arch Environ Contam Toxicol (1976) 0.75
Elevated lipoprotein (a) blood levels as the single treatable atherosclerotic risk factor in patients with coronary artery disease. J Ky Med Assoc (1993) 0.75
Aspects of microbiological and chemical quality of turmus, lupin seeds debittered by soaking in water. J Food Prot (1998) 0.75
Surface activity, cellular uptake and cytotoxicity of tricyclic psychoactive drugs in vitro. Biochem Pharmacol (1979) 0.75
Experimental investigations on the different hepatotoxic potential of erythromycin derivatives. Med Chir Dig (1976) 0.75
Relationship between surface activity and toxicity to Chang liver cultures of tricyclic antidepressants. Pharmacology (1979) 0.75
Probucol with colestipol in the treatment of hypercholesterolemia. Ann Intern Med (1984) 0.75
Colestipol and clofibrate in hypercholesterolemia. Clin Pharmacol Ther (1974) 0.75
The treatment of hyperlipoproteinemias. Ration Drug Ther (1979) 0.75
One hundred digitalis blood levels. A utilization review. Eur J Clin Pharmacol (1979) 0.75
Ethical, medical and legal issues for the use of placebos in future lipid intervention trials. Curr Opin Lipidol (2001) 0.75
Comparison of two scoring systems used to monitor diets in outpatient clinical trials. J Cardiovasc Risk (1995) 0.75
Prevention of toxicity to isolated hepatocytes by liposome entrapment of chenodeoxycholic acid. Toxicol Lett (1984) 0.75
Low-dose colestipol plus probucol for hypercholesterolemia. Am J Cardiol (1984) 0.75
Lipid-altering drugs in development. Drugs R D (1999) 0.75
Alterations of liver-cell membranes after exposure to halothane. N Engl J Med (1980) 0.75
Gas-liquid chromatography and mass spectrometric ion selective detection of sterigmatocystin in grains. J Assoc Off Anal Chem (1976) 0.75
Erythromycin estolate vs. erythromycin base, surface excess properties and surface scanning changes in isolated liver cell systems. Pharmacology (1980) 0.75
Hepatotoxicity and surface activity of tricyclic antidepressants in vitro. Toxicol Appl Pharmacol (1979) 0.75
Clinical trial design for obesity agents: a workshop report. Obes Res (1998) 0.75
Hepatotoxicity of general anesthetics on rat hepatoma cells in culture. Proc Soc Exp Biol Med (1976) 0.75
Liver cell culture toxicity of general anesthetics. Toxicol Appl Pharmacol (1976) 0.75
Hepatocyte responses to volatile anesthetics: changes in surface scanning and enzyme leakage. Anesth Analg (1979) 0.75
Comparative in vitro metabolism of aflatoxicol by liver preparations from animals and humans. Cancer Res (1977) 0.75
The clinical therapeutic implications of the Scandinavian Simvastatin Survival Study. Am J Cardiol (1997) 0.75